11-Oct-2019 | Zion Market Research
Zion Market Research has published a new report titled “Gout Therapeutics Market By Drug Condition (Antihyperuricemic Agents, Colchicine, Non-Steroidal Anti-Inflammatory Drugs, Corticosteroids, and Biologics), By Disease Condition (Acute Gout and Chronic Gout), and By Distribution Channel (Hospital Pharmacy, Online Sales, and Retail Pharmacy): Global Industry Perspective Comprehensive Analysis, and Forecast, 2018–2025”. According to the report, the global gout therapeutics market was USD 1,595 million in 2018 and is expected to generate around USD 3,010 million by 2025, at a CAGR of 9.5% between 2019 and 2025.
Gout is a type of disease caused by frequent occurrences of acute inflammatory arthritis. The symptoms of this disease include red and itchy skin, swollen joints, and limited movement of the affected body parts. Additionally, due to uric acid crystallization and its deposit in tendons adjacent tissues and joints also leads to a gout attack. The human body produces some amount of uric acid when it is broken down into purines. In recent times, the prevalence of gout has increased to a large extent, owing to the rising obese population, increasing alcohol intake, and growing smoking habits of people.
Browse the full “Gout Therapeutics Market By Drug Condition (Antihyperuricemic Agents, Colchicine, Non-Steroidal Anti-Inflammatory Drugs, Corticosteroids, and Biologics), By Disease Condition (Acute Gout and Chronic Gout), and By Distribution Channel (Hospital Pharmacy, Online Sales, and Retail Pharmacy): Global Industry Perspective Comprehensive Analysis, and Forecast, 2018–2025” Report at https://www.zionmarketresearch.com/report/gout-therapeutics-market
Due to changing lifestyles, there has been a rise in the prevalence of gout across the globe that has boosted the gout therapeutics market growth. Rising consumption of alcohol, purine-rich diet, growing kidney diseases and obesity worldwide, and rising consumption of a certain type of medication like the diuretics are likely to further boost gout incidence. Moreover, the growing adoption of biologics due to their ability to produce powerful anti-inflammatory action will also contribute to the gout therapeutics market in the future. Various drugs in clinical trials currently are expected to be launched over the forecast period, which will further propel this market. However, patent expiry and strict regulations of various drugs may hinder the gout therapeutics market on a global scale.
The gout therapeutics market is fragmented based on drug type, disease condition, and distribution channel. On the basis of drug type, the market includes antihyperuricemic agents, colchicine, non-steroidal anti-inflammatory drugs, corticosteroids, and biologics.
On the basis of the disease condition, the gout therapeutics market is bifurcated into acute gout and chronic gout. The chronic gout segment accounted for the largest share market in 2018 and is expected to remain dominant over the forecast period. This segment consists of urate-lowering agents like the uricosuric agents and xanthine oxidase inhibitors. With the introduction of urate-lowering drugs and predictable entry of new pipeline drugs, the segment is likely to show the highest growth rate in the future.
By distribution channel, the market comprises hospital pharmacy, online sales, and retail pharmacy. The retail pharmacy accounted for the largest market share in 2018 and is expected to remain dominant over the forecast period as well. The large presence of retail pharmacies globally is contributing toward this segment’s growth. However, the online sales segment is likely to register a high CAGR, owing to the rising trend of online shopping.
Europe and North America are leading regions that dominate the gout therapeutics market globally, due to the enhanced pharmaceutical research in these areas. North America is among the leading players in the market for gout therapeutics, due to a rising geriatric population base along with modernized routine disorders. Additionally, the U.S. holds the largest share for gout therapeutics market across entire North America. The Asia Pacific region is likely to witness the highest rate of growth over the forecast period in the gout therapeutics market, owing to the rising regional awareness about the disease.
Some key players in the global gout therapeutics market include Teijin Pharma, Takeda Pharmaceutical, Novartis, Mylan, Horizon Pharma, Teva Pharmaceutical, Iroko Pharmaceuticals, Hikma Pharmaceuticals, and Merck.
This report segments the global gout therapeutics market as follows:
Global Gout Therapeutics Market: Drug Type Analysis
Global Gout Therapeutics Market: Disease Condition Analysis
Global Gout Therapeutics Market: Distribution Channel Analysis
Global Gout Therapeutics Market: Regional Analysis
Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651